DE60106778D1 - Verfahren zur herstellung von vitronectin-rezeptorantagonisten - Google Patents

Verfahren zur herstellung von vitronectin-rezeptorantagonisten

Info

Publication number
DE60106778D1
DE60106778D1 DE60106778T DE60106778T DE60106778D1 DE 60106778 D1 DE60106778 D1 DE 60106778D1 DE 60106778 T DE60106778 T DE 60106778T DE 60106778 T DE60106778 T DE 60106778T DE 60106778 D1 DE60106778 D1 DE 60106778D1
Authority
DE
Germany
Prior art keywords
producing
receptor antagonists
vitronectin receptor
vitronectin
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60106778T
Other languages
English (en)
Other versions
DE60106778T2 (de
Inventor
Anuschirwan Peyman
Gerrit Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to DE60106778T priority Critical patent/DE60106778T2/de
Application granted granted Critical
Publication of DE60106778D1 publication Critical patent/DE60106778D1/de
Publication of DE60106778T2 publication Critical patent/DE60106778T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60106778T 2000-08-31 2001-08-29 Verfahren zur herstellung von vitronectin-rezeptorantagonisten Expired - Lifetime DE60106778T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE60106778T DE60106778T2 (de) 2000-08-31 2001-08-29 Verfahren zur herstellung von vitronectin-rezeptorantagonisten

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10042655 2000-08-31
DE10042655A DE10042655A1 (de) 2000-08-31 2000-08-31 Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
DE60106778T DE60106778T2 (de) 2000-08-31 2001-08-29 Verfahren zur herstellung von vitronectin-rezeptorantagonisten
PCT/EP2001/009985 WO2002018384A1 (en) 2000-08-31 2001-08-29 Process for the preparation of vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
DE60106778D1 true DE60106778D1 (de) 2004-12-02
DE60106778T2 DE60106778T2 (de) 2005-12-15

Family

ID=7654338

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10042655A Withdrawn DE10042655A1 (de) 2000-08-31 2000-08-31 Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
DE60106778T Expired - Lifetime DE60106778T2 (de) 2000-08-31 2001-08-29 Verfahren zur herstellung von vitronectin-rezeptorantagonisten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE10042655A Withdrawn DE10042655A1 (de) 2000-08-31 2000-08-31 Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion

Country Status (8)

Country Link
US (1) US6992187B2 (de)
EP (1) EP1315728B1 (de)
JP (1) JP5047445B2 (de)
AT (1) ATE280769T1 (de)
AU (1) AU2001293791A1 (de)
DE (2) DE10042655A1 (de)
ES (1) ES2232665T3 (de)
WO (1) WO2002018384A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1065207A1 (de) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridin derivate, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende pharmazeutische Zusammenfassungen
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
US8472792B2 (en) 2003-12-08 2013-06-25 Divx, Llc Multimedia distribution system
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
EP2386547B1 (de) 2005-12-29 2018-06-20 Lexicon Pharmaceuticals, Inc. Multizyklische Aminosäurederivate und Verwendungsverfahren dafür
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU684036A1 (ru) * 1976-11-01 1979-09-05 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср Способ получени производных аденина или их оптических изомеров
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
JPH1180131A (ja) * 1997-09-01 1999-03-26 Mitsubishi Chem Corp エチニルピリミジン誘導体
JP3957023B2 (ja) * 1997-11-12 2007-08-08 三菱化学株式会社 プリン誘導体及びそれを有効成分として含む医薬
EP1065207A1 (de) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridin derivate, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende pharmazeutische Zusammenfassungen
EP1065208A1 (de) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituierte Purin Derivate als Inhibitoren der Zell-Adhäsion

Also Published As

Publication number Publication date
AU2001293791A1 (en) 2002-03-13
JP5047445B2 (ja) 2012-10-10
JP2004507544A (ja) 2004-03-11
US6992187B2 (en) 2006-01-31
ATE280769T1 (de) 2004-11-15
US20040248907A1 (en) 2004-12-09
EP1315728A1 (de) 2003-06-04
EP1315728B1 (de) 2004-10-27
DE10042655A1 (de) 2002-03-14
ES2232665T3 (es) 2005-06-01
DE60106778T2 (de) 2005-12-15
WO2002018384A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
DE60214743D1 (de) Verfahren zur herstellung von fischer-tropsch-wachsen
DE60203569D1 (de) Verfahren zur Herstellung von Methanol
EA200600485A1 (ru) Способ получения производных 2-оксо-1-пирролидина
ATE250601T1 (de) Prozess zur herstellung der kristallinen form i von cabergolin
ATE280769T1 (de) Verfahren zur herstellung von vitronectin- rezeptorantagonisten
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
DE60015563D1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
DE602004003037D1 (de) Verfahren und zwischenprodukte für die herstellung von emtricitabin
DE60142201D1 (de) Verfahren zur Herstellung von einkristallinem Siliziumkarbid
ATE310735T1 (de) Verfahren zur herstellung von spirocyclischen tetronsäurederivaten
ATE352549T1 (de) Verfahren zur herstellung von desloratadin
ATE272038T1 (de) Verfahren zur herstellung von 2-alkyl-3- chlorphenolen
DE60234279D1 (de) Verfahren zur herstellung eines immunosuppresivums
ATE272637T1 (de) Verfahren zur herstellung einer substituierten imidazopyridinverbindung
ATE380183T1 (de) Verfahren zur herstellung von phenyltetrazolderivaten
ATE370950T1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
ATE330612T1 (de) Verfahren zur herstellung von benazeprilhydrochloride
ATE425143T1 (de) Verfahren zur herstellung von indolen
DE602004031727D1 (de) Neues verfahren und zwischenprodukte zur herstellung von 19-nor-steroiden
ATE297478T1 (de) Verfahren zur herstellung von orthocarbonsäuretrialkylestern
ATE466847T1 (de) Verfahren zur herstellung von 14-beta- hydroxybaccatin-iii-1,14-carbonat
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
ATE404540T1 (de) Verfahren zur herstellung von 1-substituierten 5- chlor-4methylpyrazolen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,